Last reviewed · How we verify

Fundación Salutia — Portfolio Competitive Intelligence Brief

Fundación Salutia pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
polyethylene glycol + Electrolytes polyethylene glycol + Electrolytes marketed Osmotic laxative Gastroenterology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Ahmed M Maged, MD · 1 shared drug class
  2. Amsterdam UMC, location VUmc · 1 shared drug class
  3. Azienda Policlinico Umberto I · 1 shared drug class
  4. Bayer · 1 shared drug class
  5. Benaroya Research Institute · 1 shared drug class
  6. Bo-In Lee · 1 shared drug class
  7. Braintree Laboratories · 1 shared drug class
  8. Aboca Spa Societa' Agricola · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Fundación Salutia:

Cite this brief

Drug Landscape (2026). Fundación Salutia — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/fundaci-n-salutia. Accessed 2026-05-16.

Related